Sourcing Neurosurgical Sponges in 2026: Alternatives After the Medline Recall

A supply chain is not really tested by the routine. It is tested by the categories you cannot easily substitute.

The neurosurgical patty, sponge, and strip category is one of those. It is small, specialized, served by only a handful of suppliers, and built around clinically exacting performance. When one of those suppliers steps back, the rest of the system feels it quickly. That is the situation procurement teams have been managing since March of this year, and the FDA's May 6 letter formalized what OR supply chain leaders already knew on the ground.

This post is a procurement read, not a clinical one. It looks at what happened, why this category resists fast substitution, how to think about sourcing across the rest of 2026, and where a line-card brand like Ceros fits inside that picture.

What happened, briefly

On March 13, 2026, Medline Industries issued a customer letter explaining that higher-than-expected endotoxin levels had been identified on Medline branded neurosurgical patty products, and that out-of-specification endotoxin levels might be present in product already on the market. The action covered single sterile, kitted sterile, and bulk non-sterile SKUs across the company's neuro patty, sponge, and strip line. The FDA classified the recall as Class 2.

On May 6, 2026, the FDA added neurosurgical patties, sponges, and strip devices (product code HBA) to its medical device shortages list and issued a Letter to Healthcare Providers covering the disruption. The agency has stated that the shortage is expected to continue through the end of 2026. Medline has not announced a definite market re-entry date.

The FDA letter is worth reading directly if you have not. The practical guidance to providers includes conservation, reserving product for intracranial neurosurgical operations and other cases where alternatives are unsuitable, opening packages only as needed, considering FDA-authorized alternatives appropriate to the specific surgical application, and diversifying supply sources. That last point is the one to carry into procurement planning.

This is not framed in published coverage as a Medline competence failure, and it is not framed that way here. Endotoxin findings can affect any manufacturer in any sterile-product category. The point worth carrying forward is structural, not reputational.

Why this category resists fast substitution

Neurosurgical patties, sponges, and strips do a clinically narrow job. They absorb fluid and protect delicate neural tissue during brain, spine, and microsurgical procedures. The size grid alone is exacting, from very small sponge formats used in deep-field work up through larger sizes used in broader exposures, and the X-ray detectable construction is non-negotiable for retained-foreign-body protocols.

That clinical specificity has shaped the supply side. The 510(k) registry under product code HBA is short. Public coverage of the shortage has been explicit on this point: only a small number of specialized suppliers serve this category, and that concentration is part of the structural risk that the recall exposed. The two names every neurosurgery program has heard since March are DeRoyal and American Surgical. Both have FDA clearance, both have been in the market, and both are absorbing heavy demand pressure right now. Trade coverage has openly described their capacity as limited. They were not built to absorb the full displaced volume of the category's largest branded line on a short timeline, and they have not claimed they can. That is the gap procurement teams are running into when they call those two manufacturers cold.

There is a second dynamic worth naming. When a category gets this constrained, secondary sellers and third-party distributors move in to fill the gap. Facilities buying through those channels are often paying significantly more than they would through an established manufacturer relationship, sometimes for product with less transparent sourcing or chain-of-custody. In a category this clinically sensitive, paying a premium to an unfamiliar third party is the opposite of what a resilient sourcing strategy should look like. A direct relationship with a manufacturer's representative gives a facility both better continuity and a clearer line of sight into where the product actually comes from.

The hospitals best positioned right now are not the ones at the front of the line for DeRoyal or American Surgical allocation, and they are not the ones writing premium checks to brokers. They are the ones who already had a second and third supplier relationship in place before March, who already had a clinical evaluation pathway that could move on a reasonable timeline without cutting corners, and who already had a representative on the phone who knew the building.

How procurement teams can think about sourcing through the rest of 2026

A few practical considerations matter more than usual in a constrained category.

The first is diversification rather than single-source replacement. The instinct in a shortage is to find a new primary supplier as quickly as possible and route everything there. In a category that is constrained across the board, that instinct creates a fresh single-source risk on a new vendor whose capacity is also limited. The FDA letter explicitly recommends diversifying supply sources, and that recommendation is worth reading as supply chain advice, not just inventory advice. Two or three qualified alternative relationships, with volume split across them, are sturdier than one big new contract.

The second is treating clinical evaluation as part of the qualification, not as something to retrofit afterward. Alternative neurosurgical sponge products are not perfectly interchangeable across every surgical application. The FDA's own language asks providers to consider alternatives "appropriate to the specific surgical application." Surgeons, clinical educators, and OR leadership belong in the qualification conversation from the start. Compressing a Value Analysis Committee timeline is reasonable in a shortage. Skipping the clinical input on a product that goes near neural tissue is not.

The third is planning for the full duration. The FDA's stated expectation is that the shortage continues through the end of 2026. Procurement strategies should be sized for that horizon, not for a six-week scramble. That changes how contract terms, volume commitments, and inventory positioning should be set up across the next several quarters.

The fourth is treating relationships as part of the supply structure, not as a soft variable on top of it. A purchase order placed cold to an unfamiliar manufacturer in a constrained market moves to the back of the queue. Procurement teams with an existing relationship, current compliance documentation, and a clinical contact at the manufacturer get a faster read on availability when allocation decisions are made. This is also where an independent rep firm earns its keep. The role is not to push a product. It is to compress the qualification timeline responsibly because the documentation, the conversations, and the trust are already in place. For procurement teams thinking across procedural categories rather than just one shortage, working out a broader surgical instruments and disposables view with a consultative partner is a more durable answer than chasing one allocation at a time.

Where Ceros fits

Ceros is on the Gosnell line card, and the Ceros Neuro Sponges and Strips product line is one of the reasons we can write about this topic at all without straying from our own portfolio.

Per the Ceros by Rhino public catalog, the Ceros Neuro Sponges and Strips line offers sponges in fifteen sizes ranging from one-quarter by one-quarter inch up to three by three inches, and strips in eight sizes ranging from one-quarter by six inches up to three and one-half by six inches. The products are X-ray detectable, and the sponges are packaged ten to a Count Verification Card to support retained-foreign-object protocols at the bedside. Shelf life is four years, which matters when a procurement strategy is being built for the rest of 2026 and beyond. Raw materials are sourced in the United States, the products are manufactured in the Dominican Republic, and final sterilization is performed in the United States. That sourcing footprint is worth noting in its own right, because raw material origin and final sterilization geography are increasingly part of how procurement teams weigh supply continuity, not just price.

The honest framing is supply diversification. If your facility is qualifying additional sources for neurosurgical sponges and strips through the rest of 2026, Ceros is worth a conversation alongside whatever other alternatives your team is already evaluating, and in many cases it is the line that is not already on every other procurement team's call list.

The principle behind it

Recall events are part of the medical supply landscape. They happen to large manufacturers and small ones, in commoditized categories and specialized ones, and they are usually handled by a market that has enough redundancy to absorb the disruption without much visibility to procurement teams.

Concentrated categories do not have that redundancy. The neurosurgical patty, sponge, and strip category is one of those, and the work of the next two quarters is essentially the work of putting structural diversification in place after the fact. The teams that come out of 2026 in the best position will be the ones who used this period to build relationships and qualifications that outlast the shortage, not just to fill the gap.

We are a family-owned rep firm. When a category gets hard, our job is to be useful in a quiet, specific way: to be the person who picks up the phone, who knows which questions the clinical team is going to ask before they ask them, and who can speak honestly about what a manufacturer can and cannot do right now.

If your neurosurgery program is working through alternative sourcing right now, Gosnell Medical Sales can help. We represent the Ceros Neuro Sponges and Strips line, we have established manufacturer relationships across procedural categories, and we have a clinical and operational team that can move quickly without sacrificing the evaluation process.

If you are evaluating alternatives, or want to understand what options exist beyond the two names everyone is already calling and the brokers filling the rest of the gap, reach out to us directly or connect with us on LinkedIn. The sooner facilities qualify for alternative supply, the better positioned they are for the rest of 2026.

A supply chain is built in the quiet months. It is paid back in the loud ones.